Methods for predicting clinical outcome for inhibitors of epidermal growth factor receptor for cancer patients

摘要

Method for selecting a cancer patient is reasonable or not benefit from therapeutic administration of an EGFR inhibitor, comprising the fact: A) detecting in a sample of tumor cells derived from a patient, a change in the number of copies of selected from the group consisting gene: I) in a gene amplification factor receptor epidermal growth (EGFR); Ii) a polysomy of the EGFR gene; Iii) a gene amplification receptor receptor tyrosine kinase human (HER2) type; and iv) a polysomy of the HER2 gene; B) comparing the copy number of the EGFR gene and / or HER2 in the sample of patient tumor cells with a copy number of the EGFR gene and / or HER2 coming from tumor cells they are sensitive or resistant to an EGFR inhibitor and C) selecting the patient as being reasonable benefit from therapeutic administration of the EGFR inhibitor, if the number of copies of the EGFR gene and / or HER2 in patient tumor cells is statistically similar or higher number of copies of the gene EGFR and / or HER2 in tumor cells that are sensitive to an EGFR inhibitor, or if a number of copies of the EGFR gene and / or HER2 in patient tumor cells is statistically greater than the number of copies of the EGFR gene and / or HER2 in tumor cells that are resistant to an EGFR inhibitor; or D) selecting the patient as being reasonable benefit from therapeutic administration of the EGFR inhibitor, if the number of copies of the EGFR gene and / or HER2 in patient tumor cells is statistically less than the number of copies of the EGFR gene and / or HER2 in tumor cells that are sensitive to an EGFR inhibitor, or if the number of copies of the EGFR gene and / or HER2 in patient tumor cells is statistically similar to or less than the number of copies of the EGFR gene and / or HER2 in tumor cells that are resistant to an EGFR inhibitor.